Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

St. Jude finds anti-leukemia drug increases patient fatigue

06.11.2007
Finding that dexamethasone increases fatigue in children suggests that altering timing or dosing of this drug could lessen troublesome effect on sleep and increase quality of life for patients and their families

The anti-leukemia drug dexamethasone contributes to a relentless fatigue and poor quality of sleep in children undergoing treatment for acute lymphoblastic leukemia (ALL), according to a new study from St. Jude Children's Research Hospital. The finding suggests that clinicians could improve the quality of life for these children by developing new methods of drug administration that reduce or eliminate these side effects.

The St. Jude team showed that dexamethasone significantly increased patients?fatigue, length of daytime naps, frequency of awakening at night and the amount of restlessness during sleep. The findings also suggest that before initiation of continuation therapy for ALL, health care workers should prepare patients and families to expect an increase in disrupted sleep and fatigue during dexamethasone treatment. Continuation therapy is the long-term treatment that occurs following the initial intensive use of anti-cancer drugs designed to quickly reduce the number of cancer cells.

“Parents and patients have long reported altered behaviors during dexamethasone treatment, but this is the first trial to document that disrupted sleep and fatigue are behavioral indicators of patients?response to the treatment,?said Pamela Hinds, Ph.D., R.N., director of the Division of Nursing Research at St. Jude. Hinds is the first author of this study, which appears in the online version of the journal “Cancer.?

Previous studies had found that dexamethasone was especially effective in the treatment of ALL, but that it could also cause a variety of side effects in children, including fatigue. Therefore, the St. Jude team designed the current study to determine if the direct and consistent link between dexamenthasone and fatigue and disrupted sleep in children was significant and common.

“Before we could begin to revise the way we give dexamethasone to children we had to establish if the drug routinely disrupts the sleep of children, or whether it’s only an occasional problem among specific children,?Hinds said. “We found that it’s a widespread problem across all age groups.?The study included 100 pediatric patients, with an average age of nine years, who were treated at St. Jude, Texas Children’s Cancer Center in Houston and Hospital for Sick Children in Toronto.

Researchers monitored the sleep activity of children during two consecutive five-day periods by having them wear a wristwatch-style device called an actigraph, which senses motion and stores the information on a computer chip. The children did not receive dexamethasone during the first five-day period, but were treated with the drug during the second period. In addition, parents kept a “sleep diary,?in which they recorded their daily perceptions of their child’s sleep and nap patterns during the previous 24-hour period. Children, ages 7 to 12 years, and adolescents, ages 13 to 18, completed surveys, rating how tired they were; and parents filled out surveys about their perception of their child’s fatigue.

“Now that we have demonstrated that dexamethasone is so disruptive of sleep and causes profound fatigue in children with ALL, we will study ways to reduce these troublesome side effects, while still allowing the patients to get full benefit of the treatment,?said Ching-Hon Pui, M.D., chair of the St. Jude Department of Oncology and the paper’s senior author. “This would help us continue to improve the already high quality of care we provide to children with ALL.?

Carrie Strehlau | EurekAlert!
Further information:
http://www.stjude.org

More articles from Health and Medicine:

nachricht UC San Diego cancer scientists identify new drug target for multiple tumor types
12.07.2019 | University of California - San Diego

nachricht Bacteria engineered as Trojan horse for cancer immunotherapy
04.07.2019 | Columbia University School of Engineering and Applied Science

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Megakaryocytes act as „bouncers“ restraining cell migration in the bone marrow

Scientists at the University Würzburg and University Hospital of Würzburg found that megakaryocytes act as “bouncers” and thus modulate bone marrow niche properties and cell migration dynamics. The study was published in July in the Journal “Haematologica”.

Hematopoiesis is the process of forming blood cells, which occurs predominantly in the bone marrow. The bone marrow produces all types of blood cells: red...

Im Focus: Artificial neural network resolves puzzles from condensed matter physics: Which is the perfect quantum theory?

For some phenomena in quantum many-body physics several competing theories exist. But which of them describes a quantum phenomenon best? A team of researchers from the Technical University of Munich (TUM) and Harvard University in the United States has now successfully deployed artificial neural networks for image analysis of quantum systems.

Is that a dog or a cat? Such a classification is a prime example of machine learning: artificial neural networks can be trained to analyze images by looking...

Im Focus: Extremely hard yet metallically conductive: Bayreuth researchers develop novel material with high-tech prospects

An international research group led by scientists from the University of Bayreuth has produced a previously unknown material: Rhenium nitride pernitride. Thanks to combining properties that were previously considered incompatible, it looks set to become highly attractive for technological applications. Indeed, it is a super-hard metallic conductor that can withstand extremely high pressures like a diamond. A process now developed in Bayreuth opens up the possibility of producing rhenium nitride pernitride and other technologically interesting materials in sufficiently large quantity for their properties characterisation. The new findings are presented in "Nature Communications".

The possibility of finding a compound that was metallically conductive, super-hard, and ultra-incompressible was long considered unlikely in science. It was...

Im Focus: Modelling leads to the optimum size for platinum fuel cell catalysts: Activity of fuel cell catalysts doubled

An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today.

Fuel cells may well replace batteries as the power source for electric cars. They consume hydrogen, a gas which could be produced for example using surplus...

Im Focus: The secret of mushroom colors

Mushrooms: Darker fruiting bodies in cold climates

The fly agaric with its red hat is perhaps the most evocative of the diverse and variously colored mushroom species. Hitherto, the purpose of these colors was...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on UV LED Technologies & Applications – ICULTA 2020 | Call for Abstracts

24.06.2019 | Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

 
Latest News

Tracking down climate change with radar eyes

17.07.2019 | Earth Sciences

Researchers build transistor-like gate for quantum information processing -- with qudits

17.07.2019 | Information Technology

A new material for the battery of the future, made in UCLouvain

17.07.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>